Bharat Biotech Develops India's First Coronavirus Vaccine, COVAXIN

Bharat Biotech, the Hyderabad-based vaccine maker is leading the consortia consisting of the Indian Council of Medical Research (ICMR) and the Pune-based, National Institute of Virology (NIV).

The first phase is "designed to evaluate the safety and immunogenicity of the vaccine", she explained.

India's drug control authorities have allowed Bharat Biotech to hold Phase 1 and 2 of clinical human trials after "company submitted results generated from preclinical studies, demonstrating safety and immune response", a statement issued by the firm added. The collaboration with the ICMR and the NIV was instrumental in the development of this vaccine.

The Chairman and Managing Director of the Bharat Biotech, Dr Krishna Ella said with strong support from the consortia partners and Government, the entire development process was accelerated through national regulatory protocols. In fact, it was the first in the world to begin clinical trials on March 16, according to media reports.

The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at the University of Oxford.

Hong Kong-listed CanSino Biologics said in a filing to the stock exchange that data from clinical trials showed the Chinese military vaccine had a "good safety profile" and potential to prevent disease caused by the coronavirus.

The company deployed its full strengths in R&D, manufacturing and completed the comprehensive pre-clinical studies.

The drug manufacturer said that the vaccine has been developed in a high containment facility in Hyderabad.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic".

Scientists across the globe are now working towards a vaccine faster than ever.

Reports suggest that China, which is among front-runners in the race to find a COVID-19 jab, is developing coronavirus vaccines in five categories - inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines and nucleic acid-based vaccines.

The company is also involved in the development of CoroFlu, a nasal vaccine for COVID-19, as part of an worldwide collaboration of virologists at the University of Wisconsin-Madison and vaccine firm FluGen.

According to the Ministry of Health and Family Welfare, the total COVID infections spiked to 548,318, as on June 30.



Other news